Human coronavirus OC43

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research

Retrieved on: 
Tuesday, March 14, 2023
Conference, Na'aran, Viral, RNA-dependent RNA polymerase, International Conference on Emerging Infectious Diseases, CNRS, ICAR, COVID-19, SLC, Rat, Doctor of Philosophy, CYP450, Urine, HIV disease progression rates, Cirrhosis, ABC, Antiviral Research, CET, SP, Drug resistance, Aix-Marseille University, SARS-CoV-2, Fever Dream, NS5A, BEM, Infection, Sulfur, Plasma, GUK1, Risk, ADME, Methylation, Enzyme, Patient, Metabolism, UGT1A1, Coronavirus, Phosphate, Safety, Discovery and development of NS5A inhibitors, RNA, Hepatitis C, Human coronavirus OC43, Combination, Virus, DENV, Maintenance, Architecture, GalNAc-T activation pathway, Feces, HINT1, Orthornavirae, Dengue virus, RZR, Therapy, NS5, Pharmaceutical industry, Vaccine, Flour, Phosphorus, Bemnifosbuvir, HCV

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for serious viral diseases, today announced the presentation of new Phase 1, in vitro and in vivo data that demonstrate key profile attributes of Atea’s lead drug candidate, bemnifosbuvir, for the treatment of COVID-19 and hepatitis C (HCV). Additionally, new data for AT-752 for dengue and a nucleotide analogue are being presented. These results are being presented at the 36th International Conference on Antiviral Research (ICAR 2023) taking place March 13-17, 2023 in Lyon, France.

Key Points: 
  • Additionally, new data for AT-752 for dengue and a nucleotide analogue are being presented.
  • These results are being presented at the 36th International Conference on Antiviral Research (ICAR 2023) taking place March 13-17, 2023 in Lyon, France.
  • These advantages include a higher barrier to resistance and maintenance of antiviral activity in the presence of COVID-19 variants.
  • Additionally, the combination of bemnifosbuvir and ruzasvir for the treatment of HCV demonstrated potent in vitro synergistic antiviral activity and in vivo preclinical safety without adverse interactions.

Bon Natural Life Limited Adds New Multi-Functional Health Supplements to Product Line

Retrieved on: 
Thursday, April 21, 2022
Immunity, Digestive, CEO, Nature, Delta, Plant, Population, Marketing communications, Immune system, Johns Hopkins University, Private Securities Litigation Reform Act, Food, Human coronavirus OC43, Organization, Goal, Infection, GF, Growth, Pharmacy, Review, Technology, Company, SFN, SEC, Forward-looking statement, A.A, Mouse, Perfume, Health, BON, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Dietary supplement, Sleep, Omicron

Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice.

Key Points: 
  • Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice.
  • In addition, BON also plants the highest concentration cruciferous vegetables farm to improve the large-scale production.
  • These products likely include:
    Immune system booster in soft gel capsules;
    Digestive health booster in soft gel capsules;
    Sleep aid products for mid-aged and elderly.
  • The Company undertakes no obligation to publicly revise these forwardlooking statements to reflect events or circumstances that arise after the date hereof.

DGAP-News: Marinomed Biotech AG publishes clinical data on efficacy of Carragelose lozenges against respiratory viruses including SARS-CoV-2 in the International Journal of General Medicine

Retrieved on: 
Thursday, September 9, 2021

The resulting iota-carrageenan concentrations are many times higher than the concentrations needed to inhibit 90 % of viral replication (IC90) of all tested viruses.

Key Points: 
  • The resulting iota-carrageenan concentrations are many times higher than the concentrations needed to inhibit 90 % of viral replication (IC90) of all tested viruses.
  • This indicates that the lozenges are an appropriate measure to reduce infection and potentially preventing severe illness as well as transmission within a population.
  • Carragelose has been well established to prevent respiratory infections by various viruses, including certain influenza and endemic Coronaviruses.
  • Marinomed, Marinosolv(R) and Carragelose(R) are registered trademarks of Marinomed Biotech AG.

"Corona Virus Vaccine Market Size is Projected to reach 75.75 Billion by end of 2021, Says Brandessence Market Research"

Retrieved on: 
Tuesday, March 2, 2021
Coronaviridae, Medical specialties, Nidovirales, Zoonoses, Sarbecovirus, Bat virome, Vaccination, Virology, Human coronavirus 229E, Human coronavirus OC43, Coronavirus, Human coronavirus HKU1

The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.

Key Points: 
  • The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.
  • The study provides a crucial view of global corona virus vaccine market by segmenting the market based on infection type, vaccine type and region & country level.
  • Based on infection, the corona virus vaccine market is segmented into HCoV-229E, HCoV-OC43, HKU1-CoV, NL63, MERS-CoV, New Haven CoV, SARS-CoV and SARS-CoV-2.
  • Based on vaccine type, the market is segmented into S-protein based coronavirus vaccine, live attenuated coronavirus vaccine, inactivated coronavirus vaccine, MRNA vaccine and DNA-based vaccine.

"Corona Virus Vaccine Market Size is Projected to reach 75.75 Billion by end of 2021, Says Brandessence Market Research"

Retrieved on: 
Tuesday, March 2, 2021
Coronaviridae, Medical specialties, Nidovirales, Zoonoses, Sarbecovirus, Bat virome, Vaccination, Virology, Human coronavirus 229E, Human coronavirus OC43, Coronavirus, Human coronavirus HKU1

The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.

Key Points: 
  • The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.
  • The study provides a crucial view of global corona virus vaccine market by segmenting the market based on infection type, vaccine type and region & country level.
  • Based on infection, the corona virus vaccine market is segmented into HCoV-229E, HCoV-OC43, HKU1-CoV, NL63, MERS-CoV, New Haven CoV, SARS-CoV and SARS-CoV-2.
  • Based on vaccine type, the market is segmented into S-protein based coronavirus vaccine, live attenuated coronavirus vaccine, inactivated coronavirus vaccine, MRNA vaccine and DNA-based vaccine.

FDA Issues Emergency Use Authorization for MatMaCorp's COVID-19 2SF RNA Test for the Detection of SARS-CoV-2

Retrieved on: 
Tuesday, January 12, 2021
Research, Hardware, Medical devices, Technology, Infectious diseases, Healthcare reform, Hospitals, Science, Biotechnology, FDA, Health, Public policy, Government, Sarbecovirus, Zoonoses, Infectious diseases, Medicine, Coronavirus disease, Occupational safety and health, COVID-19 testing, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Wastewater surveillance, Human coronavirus OC43, Emergency Use Authorization Status, MatMaCorp

MatMaCorps COVID-19 2SF RNA test and Solas 8 portable device are ideally suited to provide reliable results for surveillance and routine testing.

Key Points: 
  • MatMaCorps COVID-19 2SF RNA test and Solas 8 portable device are ideally suited to provide reliable results for surveillance and routine testing.
  • MatMaCorps COVID-19 2SF RNA test and Solas 8 portable detection system are designed to make COVID-19 testing accessible and cost-effective at CLIA-certified sites.
  • The test has been authorized only for the detection of RNA from SARS-CoV-2 virus and diagnosis of SARS-CoV-2 virus (COVID-19) infection, not for any other viruses or pathogens.
  • CDC: Why Rural Communities May Be at Higher Risk During the COVID-19 Pandemic, updated August 3, 2020, accessed January 11, 2021.

VBI Vaccines to Present at Upcoming Scientific Conferences

Retrieved on: 
Thursday, September 24, 2020
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Medical specialties, Health, Medicine, Infectious diseases, Zoonoses, Animal virology, Coronavirus, Common cold, Respiratory disease, Virus, Human coronavirus OC43, Human coronavirus 229E, Sci-B-Vac®, VBI-1901 and GBM, Coronaviruses, VBI Vaccines Inc.

Scientific literature suggests CMV infection is prevalent in multiple solid tumors, including glioblastoma (GBM).

Key Points: 
  • Scientific literature suggests CMV infection is prevalent in multiple solid tumors, including glioblastoma (GBM).
  • Coronaviruses are a large family of enveloped viruses that usually cause respiratory illness of varying severities, including the common cold and pneumonia.
  • Only seven coronaviruses are known to cause disease in humans, four of which most frequently cause symptoms of the common cold.
  • VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Meridian launches a novel SARS-CoV-2 antibody pair designed for developing highly sensitive rapid antigen tests from saliva samples

Retrieved on: 
Monday, September 14, 2020
Medical specialties, Medicine, Nidovirales, Zoonoses, Immune system, Human coronavirus OC43, Human coronavirus NL63, Animal virology, Coronavirus disease, Coronavirus, Severe acute respiratory syndrome coronavirus, ELISA

Intentionally designed and screened for the development of rapid saliva antigen tests, these antibodies recognize a linear epitope of the SARS-CoV-S1 trimeric protein.

Key Points: 
  • Intentionally designed and screened for the development of rapid saliva antigen tests, these antibodies recognize a linear epitope of the SARS-CoV-S1 trimeric protein.
  • The antibody pair is the first-of-its-kind, having sensitivity down to picograms per milliliter as measured by ELISA.
  • Further, the antibody pair is highly specific to the SARS-CoV-2 trimeric spike protein and does not cross react with other coronaviruses, such as SARS-CoV, HCoV-229F, HCoV-HKUI, HCoV-NL63 and HCoV-OC43.
  • A rapid COVID-19 antigen assay from saliva, which does not sacrifice sensitivity, is now possible due to this novel antibody pair.

Global Coronavirus Vaccine (SARS-CoV-2 and Others) Market Forecast to 2025

Retrieved on: 
Wednesday, June 3, 2020
Viruses, Zoonoses, Coronaviridae, In Saudi Arabia, Middle East respiratory syndrome, Coronavirus, Middle East respiratory syndrome-related coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Orthocoronavirinae, Human coronavirus OC43, CoV

DUBLIN, June 3, 2020 /PRNewswire/ -- The "Global Coronavirus Vaccine Market By Infection Type (HCoV-229E, HCoV-OC43, SARS-CoV, New Haven CoV, HKU1-CoV, MERS-CoV, SARS-CoV-2, Others), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 3, 2020 /PRNewswire/ -- The "Global Coronavirus Vaccine Market By Infection Type (HCoV-229E, HCoV-OC43, SARS-CoV, New Haven CoV, HKU1-CoV, MERS-CoV, SARS-CoV-2, Others), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.
  • The Global Coronavirus Vaccine Market is expected to grow at a robust rate during the forecast period.
  • The Global Coronavirus Vaccine Market is segmented based on infection type, vaccine type, product type, route of administration, patient type, end-user, company and region.
  • Regionally, the Global Coronavirus Vaccine Market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa.

Global Coronavirus Vaccine Market: Trends, Forecast & Opportunities (2019-2025) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 3, 2020
Health, Pharmaceutical, Viruses, Zoonoses, Coronaviridae, In Saudi Arabia, Middle East respiratory syndrome, Coronavirus, Middle East respiratory syndrome-related coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Orthocoronavirinae, Human coronavirus OC43, CoV

The "Global Coronavirus Vaccine Market By Infection Type (HCoV-229E, HCoV-OC43, SARS-CoV, New Haven CoV, HKU1-CoV, MERS-CoV, SARS-CoV-2, Others), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Coronavirus Vaccine Market By Infection Type (HCoV-229E, HCoV-OC43, SARS-CoV, New Haven CoV, HKU1-CoV, MERS-CoV, SARS-CoV-2, Others), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.
  • The Global Coronavirus Vaccine Market is expected to grow at a robust rate during the forecast period.
  • The Global Coronavirus Vaccine Market is segmented based on infection type, vaccine type, product type, route of administration, patient type, end-user, company and region.
  • Regionally, the Global Coronavirus Vaccine Market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa.